http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-132017003992-E2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02dc41d7359da467b164070ade6560bd |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate | 2017-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d464690e2a3112b671505dec13e51f20 |
| publicationDate | 2017-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-132017003992-E2 |
| titleOfInvention | use of active substance in the treatment of telangiectatic melasma |
| abstract | use of active substance in the treatment of telangiectatic melasma. The present Certificate of Addition belongs to the technological sector of the pharmaceutical industry and refers more specifically to further details of α-adrenergic receptor agonist substances which may be used in the treatment of telangiectatic melasma. Such detail includes a number of other compounds belonging to the same pharmacological group as α-adrenergic receptor agonists which, as recent studies reveal, have similar clinical effects to brimonidine. from such a certificate, the inventive concept set forth in the previous document, which now referred to compounds of the α-adrenergic receptor agonist group and more specifically to the brimonidine compound, now encompasses a plurality of compounds also belonging to the same. pharmacological group of α-adrenergic receptor agonists and having an analogous action to brimonidine. |
| priorityDate | 2017-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2435 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414161244 |
Total number of triples: 13.